Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Baxter 3Q11 | Contract Pharma

What are you searching for?

Sign in
Breaking News

Financial Report: Baxter 3Q11

BioScience revenues up 9%

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Baxter 3Q11

3Q Revenues: $3.5 billion (+8%)

3Q Earnings: $576.0 million (+10%)

YTD Revenues: $10.3 billion (+10%)

YTD Earnings: $1.8 billion (+77%)

Comments: BioScience revenues in the quarter were $1.5 billion (+9%), boosted by Gammagard Liquid, certain plasma-based therapeutics, and vaccines. Medical Products sales were $2.0 billion (+7%). 1Q10 included a charge totaling $588 million related to the recall of COLLEAGUE infusion pumps and 3Q10 included an impairment charge of $112 million associated with the company’s divestiture of its U.S. generic injectables business.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics